A randomized, double-blind, placebo-controlled, parallel-arm, multiple-dose study assessing pharmacokinetics (PK), pharmacodynamics (PD), and safety of various dose regimens of bimagrumab and routes of administration in healthy older adults
Latest Information Update: 22 Dec 2022
Price :
$35 *
At a glance
- Drugs Bimagrumab (Primary)
- Indications Cachexia; Muscular atrophy; Obesity
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 22 Dec 2022 New trial record
- 17 Dec 2022 Results published in the Clinical Pharmacokinetics